SE9300012D0 - New peptides - Google Patents

New peptides

Info

Publication number
SE9300012D0
SE9300012D0 SE9300012A SE9300012A SE9300012D0 SE 9300012 D0 SE9300012 D0 SE 9300012D0 SE 9300012 A SE9300012 A SE 9300012A SE 9300012 A SE9300012 A SE 9300012A SE 9300012 D0 SE9300012 D0 SE 9300012D0
Authority
SE
Sweden
Prior art keywords
new peptides
peptides
compounds
taining
immunosuppressants
Prior art date
Application number
SE9300012A
Other languages
English (en)
Swedish (sv)
Inventor
P W Schiller
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9300012A priority Critical patent/SE9300012D0/xx
Publication of SE9300012D0 publication Critical patent/SE9300012D0/xx
Priority to NZ259597A priority patent/NZ259597A/en
Priority to CA002152380A priority patent/CA2152380A1/en
Priority to PCT/SE1993/001090 priority patent/WO1994015959A1/en
Priority to PL93309778A priority patent/PL309778A1/xx
Priority to EP94904365A priority patent/EP0678099A1/en
Priority to JP6515914A priority patent/JPH08505386A/ja
Priority to CZ951711A priority patent/CZ171195A3/cs
Priority to KR1019950702750A priority patent/KR960700269A/ko
Priority to HU9502041A priority patent/HUT72597A/hu
Priority to AU58448/94A priority patent/AU681372B2/en
Priority to SK839-95A priority patent/SK83995A3/sk
Priority to IL10816993A priority patent/IL108169A0/xx
Priority to IS4115A priority patent/IS4115A/is
Priority to MX9400255A priority patent/MX9400255A/es
Priority to US08/176,938 priority patent/US5602099A/en
Priority to APAP/P/1994/000605A priority patent/AP508A/en
Priority to SI9400005A priority patent/SI9400005A/sl
Priority to ZA9455A priority patent/ZA9455B/xx
Priority to YU394A priority patent/YU394A/sh
Priority to CN94100129A priority patent/CN1096515A/zh
Priority to EE9400326A priority patent/EE9400326A/xx
Priority to LVP-95-197A priority patent/LV10962B/en
Priority to FI953302A priority patent/FI953302A0/fi
Priority to NO952650A priority patent/NO952650L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/70—Enkephalins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SE9300012A 1993-01-05 1993-01-05 New peptides SE9300012D0 (sv)

Priority Applications (25)

Application Number Priority Date Filing Date Title
SE9300012A SE9300012D0 (sv) 1993-01-05 1993-01-05 New peptides
CA002152380A CA2152380A1 (en) 1993-01-05 1993-12-20 New peptides
AU58448/94A AU681372B2 (en) 1993-01-05 1993-12-20 New peptides
SK839-95A SK83995A3 (en) 1993-01-05 1993-12-20 New peptides
PCT/SE1993/001090 WO1994015959A1 (en) 1993-01-05 1993-12-20 New peptides
PL93309778A PL309778A1 (en) 1993-01-05 1993-12-20 Novel peptides
EP94904365A EP0678099A1 (en) 1993-01-05 1993-12-20 New peptides
JP6515914A JPH08505386A (ja) 1993-01-05 1993-12-20 新規なペプチド
CZ951711A CZ171195A3 (en) 1993-01-05 1993-12-20 Novel peptides
KR1019950702750A KR960700269A (ko) 1993-01-05 1993-12-20 신규한 펩티드(New Peptides)
HU9502041A HUT72597A (en) 1993-01-05 1993-12-20 New peptide, pharmaceutical compositions containing them and process for producing them
NZ259597A NZ259597A (en) 1993-01-05 1993-12-20 Peptide analogs that are opioid receptor antagonists and their use as analgesic and immunosuppressive compounds
IL10816993A IL108169A0 (en) 1993-01-05 1993-12-24 New peptides
IS4115A IS4115A (is) 1993-01-05 1993-12-27 Ný peptíð
US08/176,938 US5602099A (en) 1993-01-05 1994-01-04 δ opioid receptor antagonists
MX9400255A MX9400255A (es) 1993-01-05 1994-01-04 Analogos de peptidos opioides, metodo para su preparacion y composiciones farmaceuticas que los incluyen.
APAP/P/1994/000605A AP508A (en) 1993-01-05 1994-01-05 Novel opioid analogs that are 9 (delta) opioid receptor antagonists, their syntheis and their use as analgesic and immunosupressive compounds.
SI9400005A SI9400005A (en) 1993-01-05 1994-01-05 Novel opioid peptide analogs
ZA9455A ZA9455B (en) 1993-01-05 1994-01-05 New peptides
YU394A YU394A (sh) 1993-01-05 1994-01-05 Novi peptidi koji deluju kao antagonisti opijatskih receptora i postupci za njihovu izradu
CN94100129A CN1096515A (zh) 1993-01-05 1994-01-05 新型肽
EE9400326A EE9400326A (et) 1993-01-05 1994-11-03 Opioidpeptiidi analoogid, nende valmistamise protsess ja neid sisaldavad ravimpreparaadid
LVP-95-197A LV10962B (en) 1993-01-05 1995-06-29 New peptides
FI953302A FI953302A0 (fi) 1993-01-05 1995-07-04 Uudet peptidit
NO952650A NO952650L (no) 1993-01-05 1995-07-04 Nye peptider

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9300012A SE9300012D0 (sv) 1993-01-05 1993-01-05 New peptides

Publications (1)

Publication Number Publication Date
SE9300012D0 true SE9300012D0 (sv) 1993-01-05

Family

ID=20388466

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9300012A SE9300012D0 (sv) 1993-01-05 1993-01-05 New peptides

Country Status (25)

Country Link
US (1) US5602099A (xx)
EP (1) EP0678099A1 (xx)
JP (1) JPH08505386A (xx)
KR (1) KR960700269A (xx)
CN (1) CN1096515A (xx)
AP (1) AP508A (xx)
AU (1) AU681372B2 (xx)
CA (1) CA2152380A1 (xx)
CZ (1) CZ171195A3 (xx)
EE (1) EE9400326A (xx)
FI (1) FI953302A0 (xx)
HU (1) HUT72597A (xx)
IL (1) IL108169A0 (xx)
IS (1) IS4115A (xx)
LV (1) LV10962B (xx)
MX (1) MX9400255A (xx)
NO (1) NO952650L (xx)
NZ (1) NZ259597A (xx)
PL (1) PL309778A1 (xx)
SE (1) SE9300012D0 (xx)
SI (1) SI9400005A (xx)
SK (1) SK83995A3 (xx)
WO (1) WO1994015959A1 (xx)
YU (1) YU394A (xx)
ZA (1) ZA9455B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854211A (en) * 1993-12-23 1998-12-29 Novo Nordisk A/S Compounds with growth hormone releasing properties
IS4261A (is) * 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
IL114046A0 (en) * 1994-06-20 1995-10-31 Astra Ab New opioid peptide antagonists
RU2067000C1 (ru) * 1994-06-29 1996-09-27 Владислав Исакович Дейгин Пептид и способ его получения
US6184208B1 (en) 1994-06-29 2001-02-06 Immunotech Developments Inc. Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
SE9402880D0 (sv) * 1994-08-30 1994-08-30 Astra Ab New peptide derivatives
US5780589A (en) * 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
AU708620B2 (en) * 1995-03-29 1999-08-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0837857A4 (en) * 1995-03-29 1998-08-05 Merck & Co Inc FARNESYL-PROTEIN TRANSFERASE INHIBITORS
DE19512484A1 (de) 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
SE9600769D0 (sv) * 1996-02-28 1996-02-28 Astra Ab Compounds useful as analgesic
JP2002512625A (ja) * 1997-05-29 2002-04-23 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としての複素環アミド化合物
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6306576B1 (en) * 1999-02-19 2001-10-23 Cleveland Clinic Foundation Diagnostic methods for asthma
US7601739B2 (en) 2003-08-08 2009-10-13 Virgina Commonwealth University Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
EP3160497A4 (en) * 2014-06-27 2018-01-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Conjugates for immunotherapy

Also Published As

Publication number Publication date
LV10962A (lv) 1995-12-20
CN1096515A (zh) 1994-12-21
LV10962B (en) 1997-04-20
FI953302A (fi) 1995-07-04
IL108169A0 (en) 1994-04-12
CA2152380A1 (en) 1994-07-21
FI953302A0 (fi) 1995-07-04
YU394A (sh) 1997-07-31
SI9400005A (en) 1994-12-31
SK83995A3 (en) 1996-09-04
NZ259597A (en) 1996-07-26
CZ171195A3 (en) 1996-09-11
EE9400326A (et) 1996-04-15
AU681372B2 (en) 1997-08-28
HU9502041D0 (en) 1995-09-28
ZA9455B (en) 1994-07-05
PL309778A1 (en) 1995-11-13
IS4115A (is) 1994-07-06
WO1994015959A1 (en) 1994-07-21
JPH08505386A (ja) 1996-06-11
AP508A (en) 1996-07-22
AP9400605A0 (en) 1994-01-31
HUT72597A (en) 1996-05-28
NO952650L (no) 1995-08-30
NO952650D0 (no) 1995-07-04
AU5844894A (en) 1994-08-15
KR960700269A (ko) 1996-01-19
MX9400255A (es) 1994-07-29
EP0678099A1 (en) 1995-10-25
US5602099A (en) 1997-02-11

Similar Documents

Publication Publication Date Title
SE9300012D0 (sv) New peptides
IL122345A0 (en) Benzamide derivatives their use as vasopressin antagonists processes for the preparation thereof and pharmaceutical compositions containing the same
TR199801253T2 (xx) Vitronektin resept�r� antagonistleri.
MX9702380A (es) Nuevas carboxamidas con actividad antifungica.
FR2696094B1 (fr) Nouvelles compositions pharmaceutiques contenant des cyclosporines.
DE69225588T2 (de) Azeotropische und azeotropähnliche zusammensetzungen von 1,1,2,2,-tetrafluorathan
MX9703186A (es) Antagonistas del receptor del neuropeptido y de indolilo.
IL94990A (en) Pharmaceutical compositions for the prophylaxis and/or treatment of benign porstatic hyperplasia
DE69232323T2 (de) Verwendung von Adenosinantagonisten zur Vorbeugung und Behandlung von Pankreatitis und Ulcera
IT1304793B1 (it) Miscela di stabilizzanti
DK0705100T3 (da) Terapeutiske substituerede guanidiner
BR9607560A (pt) Composições cométicas anidras contendo agentes dermatologicamente ativo
CA2237189A1 (en) 3-azetidinylalkylpiperidines or -pyrrolidines as tachykinin antagonists
ID22523A (id) Formulasi aerosol obat yang mengandung budesonida
ITBO970640A0 (it) Apparecchio per l'elettroemanazione di principi attivi.
TR199902848T2 (xx) Ergolin t�revleri ve bunlar�n somatostatin resept�r antagonist olarak kullan�mlar�
BG105256A (en) Muscarinic agonists and antagonists
PL337221A1 (en) Carboxamides as antagonists of 5-ht1f
ATE265138T1 (de) Retardformulierungen von pflanzenschutzwirkstoffen
MD502G2 (ro) Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
MX9708394A (es) Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
NO980296L (no) Forbedrede terapeutiske midler
EA200000198A1 (ru) 2-ациламинопропанамины в качестве антагонистов рецепторов тахикининов
WO1998031704A3 (en) Tachykinin antagonists